Schmidt B
Klin Padiatr. 1982 Mar;194(2):91-3. doi: 10.1055/s-2008-1033780.
The postulated importance of platelets in the pathogenesis of thromboembolic events has stimulated interest in drugs that inhibit platelet function. Clinical trials of antiplatelet agents in the secondary prevention of myocardial infarction and transient ischaemic attacks have so far been inconclusive. In children antiplatelet drugs area used on the evidence of nothing but anecdote. Optimum drug or combination of drugs and dosage are still controversial. Possible fruitful applications of platelet modifying agents such as aspirin and dipyridamole in paediatric nephrology and cardiology await further evaluation in prospective trials.
血小板在血栓栓塞事件发病机制中的假定重要性激发了人们对抑制血小板功能药物的兴趣。抗血小板药物在心肌梗死和短暂性脑缺血发作二级预防中的临床试验迄今尚无定论。在儿童中，抗血小板药物的使用仅仅基于一些传闻证据。最佳药物、药物组合及剂量仍存在争议。阿司匹林和双嘧达莫等血小板修饰剂在儿科肾脏病学和心脏病学中可能的有效应用有待前瞻性试验的进一步评估。
